Dimethyl Sulfoxide
Apexbio Technology LLC CGP 57380 522629-08-9 10mM (in 1mL DMSO)
CGP 57380 (CAS 522629-08-9) is a specific and selective inhibitor targeting the serine/threonine kinase MNK1 an enzyme implicated in translation regulation via phosphorylation of the eukaryotic initiation factor 4E (eIF4E) It inhibits MNK1 activity in vitro with an IC50 of approximately 2 2 M CGP 57380 suppresses stimulus-induced phosphorylation of eIF4E in various cellular contexts including 293 cells vascular smooth muscle cells and macrophages reducing translation of mRNAs encoding proinflammatory mediators such as TNF- IL-6 and monocyte chemoattractant protein-1 (MCP-1) Hence CGP 57380 is valuable for investigating MNK1-mediated translational control in inflammation and cell signaling
Akron Biotechnology LLC CryoSolve Syringe Kit, DMSO 55%, GMP Grade, 25 x 7 mL Syringes, AK8217-2507
Akron’s CryoSolve product is manufactured following all relevant cGMP guidelines for ancillary materials. The formulation contains sterile, filtered DMSO (Dimethyl Sulfoxide, USP/EP) and Dextran-40 (USP/EP/JP).Product Features: Manufacturing• Manufactured in compliance with cGMP guidelines• In-house sterile filtration and aseptic filling• No animal-derived materials are used in the manufacture of this product• Meets BLA requirements for ancillary materials used in cell therapy productStability• 5-year shelf life• Store at 2-8 °C• Transport with cold packsFor Use StatementFor research use or further manufacturing use in ex vivo cell therapy applications. This product is not intended for direct in vivo use or for direct clinical use as a drug, therapeutic, biologic, or medical device.
Apexbio Technology LLC Irinotecan(Synonyms: CPT-11, Campto, Camptosar, irinotecan hydrochloride, Irinotecan HCl, irinotecan hydrochloride trihydrate), 10mM (in 1mL DMSO), CAS: 97682-44-5.
Irinotecan (CAS 97682-44-5) also known as CPT-11 is an anticancer prodrug that acts as an inhibitor of topoisomerase I Upon enzymatic activation by carboxylesterase (CCE) to its potent metabolite SN-38 it stabilizes the DNA-topoisomerase I cleavable complex causing DNA damage and apoptosis In vitro studies show Irinotecan inhibits various colorectal cancer cell lines including LoVo (IC50 15 8 M) and HT-29 (IC50 5 17 M) Additionally xenograft models such as COLO 320 demonstrate pronounced tumor growth suppression Irinotecan is widely utilized in research to investigate DNA damage mechanisms and therapeutic efficacy in colorectal cancer
Apexbio Technology LLC BYL-719 1217486-61-7 10mM (in 1mL DMSO)
BYL-719 (CAS 1217486-61-7) is a selective inhibitor of PI3K demonstrating minimal activity against PI3K or isoforms Through targeting PI3K an essential node frequently dysregulated via PIK3CA mutations in various cancers BYL-719 effectively disrupts downstream proliferative signaling In biochemical assays BYL-719 shows potent inhibition of PI3K with an IC50 of 5 nM Preclinical evaluations indicate dose-dependent antitumor efficacy in xenograft tumor models and proliferation arrest and apoptosis induction in multiple myeloma cell lines exhibiting PIK3CA overexpression Clinically initial studies reveal manageable safety profiles and preliminary antitumor responses notably in PIK3CA-mutant malignancies supporting continued exploration in oncology research settings
Sigma Aldrich Fine Chemicals Biosciences Dimethyl sulfoxide, 67-68-5, MFCD00002089, 1L
Molecular Formula: (CH3)2SO, Molecular Weight: 78.13, Beilstein Registry Number: 506008, Assay: ≥99.5% (GC)
Apexbio Technology LLC Lonidamine 50264-69-2 10mM (in 1mL DMSO)
Lonidamine (AF-1890) is a cell metabolism inhibitor targeting mitochondrial pyruvate carrier and hexokinase exhibiting inhibitory activity with a Ki value of approximately 2 5 M Through these targets it disrupts glycolytic metabolism by impairing aerobic glycolysis processes common in tumor cells Researchers utilize Lonidamine primarily to investigate metabolic pathways implicated in cancer cell energy production alterations in mitochondrial functions and related metabolic disorders Additionally Lonidamine is employed experimentally in studies examining mitochondrial dysfunction-associated conditions and inflammatory responses including pulmonary fibrosis
Apexbio Technology LLC XL019 945755-56-6 10mM (in 1mL DMSO)
XL019 (CAS 945755-56-6) is a selective inhibitor targeting Janus kinase 2 (JAK2) with an IC50 of 2 2 nM JAK2 regulates signaling pathways controlling erythroid granulocytic and megakaryocytic lineage differentiation via cytokine and hematopoietic growth factor receptors including erythropoietin and thrombopoietin receptors XL019 demonstrates high selectivity for JAK2 over related kinases (e g JAK1 TYK2) In mouse models bearing HEL 92 1 7 xenografts oral administration of XL019 significantly reduced tumor growth XL019 is evaluated clinically as a candidate for treating primary myelofibrosis and secondary myelofibrosis associated with polycythemia vera or essential thrombocythemia
Apexbio Technology LLC LY2157299(Synonyms: Galunisertib, LY-2157299, LY2157299 monohydrate, LY2157299 hydrate, LY2157299 free base), 10mM (in 1mL DMSO), CAS: 700874-72-2.
LY2157299 (CAS 700874-72-2) is a small-molecule antagonist that selectively targets the transforming growth factor-beta type I receptor (T RI) By blocking signaling through T RI it prevents phosphorylation of downstream effectors Smad2 and Smad3 thereby interfering with the TGF- signaling pathway Preclinical studies indicate LY2157299 inhibits 1-integrin activation reduces tumor cell invasion lowers connective tissue growth factor (CTGF) production and suppresses angiogenesis Currently in phase II clinical trials LY2157299 is being investigated primarily for therapeutic potential against hepatocellular carcinoma and glioblastoma
Apexbio Technology LLC Rimonabant 168273-06-1 10mM (in 1mL DMSO)
Rimonabant (SR141716) is a selective antagonist targeting the cannabinoid type 1 (CB1) receptor It exhibits affinity for CB1 receptors with a Ki of approximately 1 8 nM contrasting with a lower affinity for CB2 receptors (Ki 514 nM) Through blocking CB1 receptor signaling this compound is primarily utilized experimentally to investigate behaviors associated with appetite control energy balance and substance consumption Studies using animal models demonstrate that administration of Rimonabant reduces intake of palatable foods and beverages as well as sucrose and alcohol consumption highlighting its relevance in obesity feeding behavior and addiction-related research contexts
Apexbio Technology LLC Calpain Inhibitor II, ALLM 136632-32-1 10mM (in 1mL DMSO)
Calpain inhibitor II (also termed ALLM or CPI-2) is a membrane-permeable inhibitor targeting calpain I calpain II as well as cathepsin L and B Calpain inhibition by this compound can activate apoptosis via caspase-mediated pathways Studies conducted in acute lymphoblastic leukemia (ALL) cell lines (such as ALL-1 RS4 11 JURKAT) and non-Hodgkin s lymphoma (NHL) cells (including RAMOS DAUDI) revealed apoptosis induction at concentrations of 50 100 M Additionally apoptosis triggered by calpain inhibitor II appears independent of tyrosine kinases BTK and LYN Unlike calpain inhibitor I calpain inhibitor II does not influence NF- B signaling nor sensitize tumor cells to TRAIL-induced apoptosis This inhibitor is widely employed in apoptosis-related research and studies exploring calpain-associated cellular pathways